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The development of an anti-HIV microbicide is critical in the fight against the spread of HIV. It is shown
here that the covalent linking of compounds that bind gp120 with compounds that bind gp41 can inhibit HIV
entry even more potently than individual inhibitors or noncovalent combinations. The most striking example
involves griffithsin, a potent HIV inhibitor that binds to the surface of HIV gp120. While griffithsin inhibits HIV
Env-mediated fusion in a CCR5-tropic cell-cell fusion assay with a 50% inhibitory concentration (IC50) of
1.31  0.87 nM and the gp41-binding peptide C37 shows an IC50 of 18.2  7.6 nM, the covalently linked
combination of griffithsin with C37 (Griff37) has an IC50 of 0.15  0.05 nM, exhibiting a potency 8.7-fold
greater than that of griffithsin alone. Similarly, in CXCR4-tropic cell-cell fusion assays, Griff37 is 5.2-fold more
potent than griffithsin alone. In viral assays, both griffithsin and Griff37 inhibit HIV replication at midpico-
molar levels, but the linked compound Griff37 is severalfold more potent than griffithsin alone against both
CCR5- and CXCR4-tropic virus strains. Another example of this strategy is the covalently linked combination
of peptide C37 with a variant of the gp120-binding peptide CD4M33 (L. Martin et al., Nat. Biotechnol.
21:71–76, 2003). Also, nuclear magnetic resonance (NMR) spectra for several of these compounds are shown,
including, to our knowledge, the first published NMR spectrum for griffithsin.
About 2.7 million people are infected with HIV each year,
and women constitute 50% of the 33 million people living with
AIDS (57). In the developing world, effective prevention strat-
egies are lacking, often because women have limited freedom
to choose sexual situations or to insist on condom use. There-
fore, the development of an anti-HIV microbicide is extremely
important. Properties that are desirable in a microbicide include
the ability to inhibit HIV infection effectively at low concentra-
tions, the ability to be applied topically on a regular basis
without causing inflammation, stability to fluctuating temper-
atures, and inexpensive production.
The early events in an HIV infection in T cells can be
described as follows. The HIV envelope protein gp120 first
makes contact with the human cell surface protein CD4, which
causes conformational changes in gp120. The gp120–CD4 in-
teraction facilitates the formation and exposure of the binding
site on gp120 for its coreceptor on the human cell, the chemo-
kine receptor CCR5 (R5) (or CXCR4, or both for some
strains) (2, 31, 52, 55). These HIV-cell interactions lead to the
exposure of the HIV protein gp41, which mediates cell fusion.
gp41 exists as a trimer with three major segments: the N-
terminal fusion peptide (FP), which is inserted into the cell; the
so-called N-terminal heptad repeat; and the C-terminal heptad
repeat. After the fusion peptide has been inserted into the cell
membrane, the N-terminal and C-terminal segments come to-
gether to form a 6-helix bundle, a “trimer of hairpins” (re-
viewed in references 15 and 51). This action has the effect of
pulling the viral membrane surface close to the cellular sur-
face, facilitating the formation or stabilization of a viral pore.
It has been reported recently that these events may occur
partly in the endosome: early binding events in cell fusion may
occur at the cell surface, after which the entire complex is
internalized into an endosome for the final fusion process (39).
Several compounds have been shown to be successful in the
inhibition of early events in HIV infection (entry inhibition)
(23, 24, 58). Griffithsin is an alga-derived entry inhibitor that is
a leading candidate for a protein microbicide, having been
shown to inhibit HIV infection potently (16, 40), to be stable at
warm temperatures and in the low-pH environment of cervical
fluid (16), and, recently, to be able to be produced in gram
quantities by overexpression in plants (41). The mechanism of
action of griffithsin is likely based on its ability to bind the
saccharides (particularly mannose) that cover the surfaces of
both HIV gp120 and gp41 (40). As evidence that the mecha-
nism of this inhibition involves binding of griffithsin to the
glycosylated surface of gp120/gp41, exogenous addition of sev-
eral types of individual saccharides has been shown to block
the ability of griffithsin to inhibit HIV (40). Also, griffithsin
crystallizes in the presence of mannose (62), glucose, and N-
acetylglucosamine (64), in each case revealing three saccharide
binding sites per monomer. A smaller molecule that is tar-
geted to the gp120–CD4 interaction is the designed peptide
CD4M33. This 27-amino-acid peptide has been shown to bind
gp120 tightly, although micromolar concentrations are re-
quired for inhibition in cell-cell fusion assays using vaccinia
virus technology (38).
Another very effective anti-HIV strategy has been to inhibit
the formation of the gp41 “trimer of hairpins”. This has been
accomplished effectively by peptides that bind to the helical
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regions of gp41, disallowing the formation of the full 6-helix
bundle (51). The T-20 molecule is such a peptide that is derived
from the C-terminal heptad repeat of gp41 (a “C-peptide”) and
effectively binds the N-terminal region of the protein (4, 33, 47).
T-20 is currently in clinical use, and further work has also focused
on the similar C-peptides C34 and C37, which are nearly identical
to each other (differing by three extra amino acids at the N
terminus for C37) and which also bind to the N-terminal region of
gp41 and prevent the formation of the 6-helix bundle that is
critical for viral fusion (5, 36, 50, 51).
We hypothesized that a single compound with the capability
of interrupting both the gp120–CD4 interaction and the for-
mation of the gp41 6-helix bundle could have several advan-
tages. From a structural standpoint, the physical distance be-
tween target binding areas for linked compounds is not large,
since gp120 and gp41 are part of the same complex in the viral
spike. Functionally, a linked compound may improve binding
affinity and/or specificity over that of its individual counterparts.
Such a compound may have advantages in terms of the ability to
target the virus under conditions of blood flow or in a physiolog-
ical environment. Finally, an inhibitor encompassing two separate
strategies may provide comprehensive protection against multiple
clades of virus even in the event of viral mutation.
In the present study, we tested several linked compounds
that carry out the strategy of binding both gp120 and gp41. It
was found that one compound, griffithsin covalently linked via
a 16-amino-acid peptide linker with the gp41-binding peptide
C37 (Griff37), is effective at lower concentrations than griffith-
sin alone or griffithsin in combination with C37 (1:1) in cell-cell
fusion assays and in viral assays. Griff37 also exhibits a great
deal of specificity under conditions of washout and competi-
tion. Overall, this and the other HIV inhibitors reported here
may be useful as general anti-HIV therapeutics or, more spe-
cifically, as anti-HIV microbicides.
MATERIALS AND METHODS
Protein production and purification. Two peptide fusion inhibitors, N-acety-
lated, C-terminally amidated C37 and N-acetylated, C-terminally amidated
C37(Q652L), were obtained from Genescript (Piscataway, NJ). The synthesized
peptide CD4M33 was kindly provided by Loïc Martin. The genes for GriffC37
and C37CD4M33C1F23 (the gp41-binding peptide C37 covalently linked via a
16-amino-acid peptide linker with CD4M33C1F23) DNA were synthesized by
Genscript. All the constructs were placed in pET-15b (Novagen, Madison, WI).
The amino acid sequence of CD4M33C1F23 (defined in reference 36 with Cys at
position 1 and Phe at position 23) is CNLHF CQLRC KSLGL LGKCA GSFCA
CV. The amino acid sequence of the linker used for Griff37 as well as for
C37CD4M33C1F23 is SSSGG GGSGG GSSSG S, with minor variations between
the different constructs due to cloning procedures. The gene for griffithsin and
Griff37 includes a 6-histidine affinity tag as well as a thrombin cleavage site,
similar to that previously described (22). The sequence for Griff37 is MGGSS
HHHHH HSSGL VPRGS LTHRK FGGSG GSPFS GLSSI AVRSG SYLDA
IIIDG VHHGG SGGNL SPTFT FGSGE YISNM TIRSG DYIDN ISFET
NMGRR FGPYG GSGGS ANTLS NVKVI QINGS AGDYL DSLDI YYEQY
SSSGG GGSGG GSSSG SHTTW MEWDR EINNY TSLIH SLIEE SQNQQ
EKNEQ ELL. The sequence for C37CD4M33C1F23 is MHHHH HHIEG
RHTTW MEWDR EINNY TSLIH SLIEE SQNQQ EKNEQ ELLSS SGGGG
SGGGG SSSSC NLHFC QLRCK SLGLL GKCAG SFCAC V.
Griffithsin was expressed in Escherichia coli BL21(DE3) (Novagen) cells in
Luria-Bertani (LB) broth. Protein production was induced upon the addition of
isopropyl--D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM,
followed by incubation for 4 h at 37°C. Pellets from these cells were resuspended
in a 30-ml solution (500 mM NaCl, 20 mM Tris [pH 8], 10 mM benzamidine) and
were then French pressed twice at 16,000 lb/in2. After centrifugation for 1 h at
17,000  g, the supernatant was loaded onto a Ni chelating column (Amersham
Pharmacia Biotech) equilibrated with 50 mM Tris (pH 8.0)–500 mM NaCl and
was eluted with a gradient using 500 mM imidazole, 50 mM Tris (pH 8.0), and
500 mM NaCl. The fractions containing purified protein were dialyzed in a buffer
(20 mM Tris [pH 8.0]) at 4°C overnight. The concentrated protein was further
purified on a C4 reversed-phase chromatography column (Vydac, Hesperia, CA)
and was then lyophilized in a Labconco freeze-dry system (Labconco Corpora-
tion). For nuclear magnetic resonance (NMR) and some functional studies,
protein was produced in minimal medium with 15NH4Cl as the sole nitrogen
source, and the same purification procedure was used after production. In early
preparations, cleavage of the N-terminal histidine tag at the thrombin site was
attempted by incubation at room temperature in the presence of thrombin. This
attempt was unsuccessful, so experiments proceeded in the presence of the His
tag for griffithsin, Griff37, Griff37(Q652L), Griff37-shortlink, Griff37(I642D),
and griffithsin covalently linked via a 16-amino-acid peptide linker with
CD4M33C1F23 (GriffCD4M33C1F23). Others have shown that the presence of an
N-terminal His tag does not affect the activity of griffithsin (22, 40).
Griff37, Griff37(Q652L), Griff37-shortlink, Griff37(I642D), GriffCD4M33C1F23,
and C37CD4M33C1F23 were expressed in BL21(DE3) either in LB medium or in
minimal medium as indicated above, although these proteins were found in the
inclusion body. Therefore, after induction for 4 h upon addition of 1 mM IPTG
at 37°C, the cells were resuspended in 30 ml of 5 M guanidinium chloride–500
mM NaCl–20 mM Tris (pH 8.0) and were then French pressed at 16,000 lb/in2.
After centrifugation for 1 h at 17,000  g to remove undissolved material, the
supernatant was loaded onto a Ni chelating column (Amersham Pharmacia
Biotech) equilibrated with 5 M guanidinium, 50 mM Tris (pH 8.0), and 500 mM
NaCl. Elution was carried out with 5 M guanidinium, 500 mM imidazole, 50 mM
Tris (pH 8.0), and 500 mM NaCl. Fractions containing purified protein were
combined; -mercaptoethanol was added to a final concentration of 10 mM; and
the mixture was incubated for 2 h with slow stirring. The protein was then
dialyzed in 20 mM Tris (pH 8.0) at 4°C overnight, and it was further purified as
described above, by C4 reversed-phase chromatography followed by lyophiliza-
tion. For C37CD4M33C1F23, a further step of proteolytic cleavage of the His tag
by factor Xa was added (the reaction buffer consisted of 50 mM Tris-HCl [pH
7.5], 150 mM NaCl, and 1 mM CaCl2). Cleaved protein was finally purified by C4
reversed-phase chromatography and was then lyophilized in a Labconco freeze-
dry system.
The proteins were analyzed by mass spectrometry on an Agilent 1100 high-
performance liquid chromatograph (HPLC) and a Thermo Fisher LCQ ion trap
mass spectrometer (Stanford University). Experimentally obtained Mrs (with
expected values based on amino acid sequences shown in parentheses) are as
follows: for griffithsin, 14,552 (14,554, assuming N-terminal Met cleavage); for
Griff37, a broad peak at 20,544 (20,519); for Griff37(Q652L), 20,259 (20,504);
and for C37CD4M33C1F23, 8,696 (8,709).
Cell culture. Seven cell lines were used. (i) HeLa-ADA cells, which stably
express HIV-1 Env from the CCR5-tropic strain ADA, were maintained in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) plus 2 M methotrexate (Sigma) as a selective reagent. This
cell line was a kind gift from M. Alizon and Anne Brelot (Cochin Institute, Paris,
France) (43). (ii) HeLa-P5L cells, which stably express the human receptors CD4
and CCR5, were maintained in RPMI-1640 supplemented with 10% FBS plus 0.5
mg/ml zeocin (Invitrogen) for selection of CCR5 expression. They were a kind
gift from M. Alizon and Anne Brelot (Cochin Institute, Paris, France) (43). (iii)
HeLa-TZM-bl cells, which stably express the human receptors CD4, CCR5, and
CXCR4, were maintained in DMEM supplemented with 10% FBS. This cell line
was obtained through the NIH AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH, and was a gift to that program from John
C. Kappes, Xiaoyun Wu, and Tranzyme, Inc. (13, 42, 56, 59). (iv) HL2/3 cells,
which stably express HIV-1 Env and Tat from the CXCR4-tropic strain HXB2,
were obtained through the NIH AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH, and were a gift to that program from
Barbara K. Felber and George N. Pavlakis (8). The cells were maintained in
DMEM supplemented with 10% FBS and 500 g/ml G418. (v) MAGI-CCR5
cells, which stably express human CD4 and CCR5, naturally express CXCR4, and
contain an HIV-1 long terminal repeat (LTR)–-galactosidase reporter gene
construct, were maintained in DMEM supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, 100 g/ml streptomycin, 300 g/ml L-glutamine, 0.2
mg/ml G418, 0.1 mg/ml hygromycin B, and 1 g/ml puromycin. These cells were
obtained through the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH, and were a gift to that program from Julie
Overbaugh (3). (vi) 293FT cells were maintained in DMEM supplemented with
10% FBS and were a kind gift from Jennifer Manilay; they were originally
obtained from Invitrogen (Carlsbad, CA). (vii) Mouse 3T3 cells (a kind gift from
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Jean Phillipe Pellois; originally obtained from the American Type Culture Col-
lection [ATCC]) were maintained in DMEM supplemented with 10% FBS.
In addition, fresh human peripheral blood mononuclear cells (PBMCs) were
isolated and used in antiviral assays as previously described (32, 48).
Virus isolates. HIV-1 isolates were obtained from the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH, as follows:
HIV-1 Ba-L from Suzanne Gartner, Mikulas Popovic, and Robert Gallo (18, 44);
HIV-1 Ada-M (referred to below as HIV-1 ADA) from Howard Gendelman
(19–21, 60); HIV-1 92HT599 from Neal Halsey and the DAIDS, NIAID; HIV-1
IIIB from Robert C. Gallo (45, 46, 49); HIV-1 91US005 from Beatrice Hahn and
the DAIDS, NIAID; and NL4-3 from Malcolm Martin (1). HIV-1 Ba-L,
92HT599, NL4-3, and 91US005 were used for PBMC assays, while HIV-1 Ba-L,
ADA, and IIIB were used for antiviral assays using MAGI cells (multinuclear-
activation galactosidase indicator cells).
Cell-cell fusion assay. HIV-1 envelope-mediated cell-cell fusion assays have
been described elsewhere (43). Briefly, for the CCR5-tropic fusion assay, 104
HeLa-P5L cells (target) per well were seeded in a 96-well plate. After12 h, the
medium was replaced with 50 l RPMI-1640. Serial dilutions of inhibitor were
added to the wells of the plate: 20 l of protein or peptide was added to the first
well and mixed; then 20 l was removed and added to the next well; and so on.
A total of 104 HeLa-ADA cells (effector) in 50 l RPMI-1640 were then added
to each well (total, 100 l medium per well). The cells were allowed to fuse for
24 h at 37°C. Cells were then lysed by the addition of 0.5% NP-40 (US Biological)
in phosphate-buffered saline (PBS) for 30 min, after which 8 mM substrate
(chlorophenol red--D-galactopyranoside [CPRG]; Calbiochem) in PBS with 20
mM KCl and 10 mM -mercaptoethanol (Sigma) was added, and the cells were
assayed for -galactosidase activity. The absorbance at 570 nm (signal) divided
by the absorbance at 630 nm (background) was measured. The percentage of
cell-cell fusion was calculated as [100  (mean absorbance of the treated well 
mean absorbance of the HeLa-P5L-only well)]/(mean absorbance of the un-
treated wellmean absorbance of the HeLa-P5L-only well). The “treated” wells
contained an inhibitor, while “untreated” wells contained effector cells plus
target cells in the absence of inhibitors. KaleidaGraph (Synergy Software, Read-
ing, PA) was used to fit the data into a four-parameter logistic equation. Some
combinations of compounds were assessed for possible synergistic effects by
calculating the combination index (CI) (7). P values were obtained using an
unpaired, 2-tailed Student t test in Microsoft Excel. The tables in the supple-
mental material show more comparisons by this method.
In the CXCR4-tropic fusion assay, HeLa-TZM-bl cells were used as target
cells and HL2/3 cells were used as effector cells. The rest of the procedure was
identical to that for the CCR5-tropic fusion assay.
In the competition CCR5-tropic fusion assay, 5  103 HeLa-P5L cells were
seeded together with 5  103 3T3 cells per well. The rest of the procedure was
identical to the normal CCR5-tropic fusion assay.
In the low-temperature CCR5-tropic fusion assay, the addition of effector cells
to target cells was immediately followed by 2 h of incubation at 16°C. Afterwards,
the plate was returned to the 37°C cell incubator for 24 h.
For the washout assay, HeLa-ADA or HeLa-P5L cells (104 cells) were seeded
in a 96-well plate the day before the assay. After the formation of the inhibitor
gradient by serial dilution, as described above, the cells remained at room
temperature for 30 min. Afterwards, the medium containing the inhibitor was
removed, and every well was washed with PBS twice. A new medium without
inhibitor was added, and the complementary cells (HeLa-P5L cells or HeLa-
ADA cells) were seeded in the plate.
Single-round infection assay. HIV virions in which vpr and env had been
deleted were used to make single-round infectious particles as follows. Plasmids
pNL-luc3-RE, containing the firefly luciferase gene, pSV-ADA(R5), and
pSV-JRFL(R5) were kind gifts from Nathaniel Landau (10). For virus produc-
tion, 293FT cells were doubly transfected with pNL-luc3-RE and either the
pSV-ADA or the pSV-JRFL plasmid according to the product manual (47a).
Forty-eight hours posttransfection, the supernatant was harvested, centrifuged at
low speed, and filtered with a 0.45-m-pore-size syringe filter. This viral stock
was stored at 80°C. For the assay, 104 TZM-bl cells per well were seeded in a
96-well plate. The next day, the medium was removed and replaced with 50 l of
new medium. Serial dilutions of the inhibitor were carried out in the wells of the
plate: 20 l of protein or peptide was added to the first well and mixed; then 20
l was removed and added to the next well; and so on. Virus was added in an
amount sufficient to produce a luciferase signal between 60,000 and 80,000
arbitrary units for the ADA-env pseudovirus (while the noninfected-cell control
gave 600 arbitrary units) and between 40,000 and 60,000 arbitrary units for the
JR-FL-env pseudovirus. The total volume of medium per well after pseudovirus
addition was 100 l. After 24 h, the old medium was removed and replaced with
new medium. Another 24 h later, the medium was removed, and the cells were
lysed using Glo lysis buffer (Promega) according to the manual. The luciferase
substrate was then added (Luciferase assay system; Promega), and the plate was
read using an Orion II microplate luminometer (Berthold Techniques, Ger-
many). For Griff37(I642D) and Griff37-shortlink, the CPRG substrate was used
as described for the cell fusion assay. The percentage of viral infection was
calculated as [100  (mean absorbance of the treated well  mean absorbance
of the TZM-only well)]/(mean absorbance of viral infection in the absence of
inhibitor  mean absorbance of the TZM-only well). The results were plotted
using Microsoft Excel, and the 50% and 90% inhibitory concentrations (IC50 and
IC90) were calculated using a linear equation fitted between two experimental
points surrounding the IC50 or IC90.
MAGI antiviral assays. The CCR5- and CXCR4-tropic MAGI antiviral assays
were both performed using MAGI-CCR5 cells in a manner identical to that for
the CCR5-tropic HIV-1 entry assay described previously (32), except that the
virus and test compounds were left in the culture for the entire 48-h incubation
period, in contrast to the washing out of the virus and test compound 3 h
postinfection for the HIV-1 entry assay.
HIV-1 strains Ba-L and ADA were used for the CCR5-tropic assays, and
HIV-1 strain IIIB was used for the CXCR4-tropic assays. Coreceptor depen-
dence for each of the viruses used to infect MAGI-CCR5 cells, which express
both CCR5 and CXCR4, was verified by the use of AMD3100 (CXCR4 inhibitor;
positive-control inhibitor for IIIB and negative-control inhibitor for Ba-L and
ADA) and TAK779 (CCR5 inhibitor; positive-control inhibitor for Ba-L and
ADA and negative-control inhibitor for IIIB) as control compounds (data not
shown). Data were processed in a manner similar to that described above for the
single-round infection assay. In these cell-based assays, cell viability and 50%
toxic concentrations (TC50s) were derived with a commercially available soluble
tetrazolium-based MTS reagent (CellTiter 96 AQueous One Solution cell pro-
liferation assay) by using a colorimetric method for determining the number of
viable cells in proliferation, cytotoxicity, or chemosensitivity assays. All com-
pounds tested showed no toxicity at the highest tested concentration (100 nM for
C37; 10 nM for griffithsin and Griff37) (32).
NMR spectroscopy. Samples that were isotopically labeled with 15N were
prepared by growing BL21(DE3) containing the expression vector pET-15b in
the presence of minimal medium containing 15NH4Cl as the sole nitrogen source
as described above. Samples were dissolved in 20 mM sodium phosphate buffer
(pH 7.0) with 5% D2O and a small amount of 2,2-dimethyl-2-silapentane-5-
sulfonate (DSS) for spectral referencing (61). The samples were placed in Shi-
gemi tubes (Shigemi, Inc., Allison Park, PA). Spectra were measured at 25°C on
a four-channel 600-MHz Bruker Avance III spectrometer equipped with a
GRASP II gradient accessory and a TCI cryoprobe. 1H-15N correlation spectra
were measured with 760 complex points in the 1H dimension and 64 complex
points in the 15N dimension, were processed using the nmrPipe program, and
were visualized using nmrDraw (11).
RESULTS
Strategically linked compounds are potent in R5-tropic cell-
cell fusion assays. We hypothesized that linking a gp120-bind-
ing protein with a gp41-binding protein could lead to an even
more potent compound, because potentially both gp120 and
gp41 could be blocked from mediating the viral entry process.
As a test of this hypothesis, the potent HIV entry inhibitor
griffithsin was covalently linked via a 16-amino-acid peptide
linker with the gp41-binding peptide C37 to form “Griff37.”
Cell-cell fusion assays represent a common method of deter-
mining the antiviral potencies of many compounds. In this
technique, HeLa cells presenting the human proteins CD4,
CCR5, and/or CXCR4 on their surfaces (target cells) are com-
bined with HeLa cells presenting the HIV-1 Env proteins
gp120 and gp41 on their surfaces and HIV-1 Tat in their
cytoplasm (effector cells). The cells fuse by interaction of their
respective surface proteins in an event that generally mimics
the HIV entry process. The extent of cell-cell fusion can be
measured using a reporter assay, because -galactosidase in
the target cells is expressed under the control of the HIV-1
LTR promoter, which is activated by Tat from the effector cell
upon fusion (43).
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The results of CCR5-tropic cell-cell fusion assays are shown
in Fig. 1 and Table 1. Griffithsin alone performs well, with an
IC50 of 1.31  0.87 nM, and the C-peptide C37 has an IC50 of
18.2  7.5 nM in this assay. The two proteins in combination
without being linked inhibit quite well, exhibiting an IC50 of
0.46 nM (for each protein, for a total concentration of 0.91 nM
at 50% inhibition). However, when griffithsin and C37 are
covalently joined by a 16-amino-acid linker to form Grft-
linker-C37 (referred to here as Griff37), the effectiveness of
the compound in the fusion assay increases dramatically, giving
an IC50 of 0.15  0.05 nM (Fig. 1A; Table 1), which is 8.7-fold
greater than that of griffithsin alone. It has been reported that
the activity of C-peptides can be enhanced by making the point
substitution Q652L (53), so this substitution was made in the
linked compound. Griff37(Q652L) was produced and purified,
but in the CCR5-tropic fusion assay, this compound had ap-
proximately the same effectiveness as Griff37 (Table 1). Con-
versely, substitution of Asp for Ile at position 642 in C37 has
been reported to diminish the activity of C37 (28), so this
I642D substitution was made in Griff37, and the resulting pro-
tein showed 2.4-fold worse inhibition than that of Griff37 in the
fusion assay, but still 2-fold better than that of griffithsin alone
(data not shown). When the linker between griffithsin and C37
was shortened to 4 amino acids, the resulting protein was
1.6-fold less potent than Griff37 but still 3.1-fold more potent
than griffithsin alone (data not shown).
As a further test of the overall strategy to link gp120-
binding molecules with gp41-binding molecules, peptide
C37 was linked with a 16-amino-acid linker to a modified
version of peptide CD4M33, an HIV inhibitor that was de-
signed to bind gp120 in a manner similar to the CD4 protein
(38). While the published peptide contains unnatural amino
FIG. 1. Cell-cell fusion assays. IC50s determined by various numbers (n) of independent experiments carried out in triplicate were averaged.
(A) CCR5-tropic fusion assay using HeLa-ADA effector cells and HeLa-P5L CCR5-bearing target cells. The average IC50s of the compounds
tested are as follows: griffithsin, 1.31  0.87 nM (n  22); Griff37, 0.148  0.05 nM (n  11); C37, 28.2  8.3 nM (n  7); griffithsin plus C37
(1:1), 0.911  0.37 nM (n  4). (B) CXCR4-tropic fusion assay using HL2/3 effector cells and TZM-bl CXCR4-bearing target cells. The average
IC50s of the compounds tested are as follows: griffithsin, 0.468  0.27 nM (n  21); Griff37, 0.088  0.03 nM (n  5); C37, 2.70  1.3 nM (n 
6); griffithsin plus C37 (1:1), 0.542  0.39 nM (n  5).
TABLE 1. Inhibition of HIV Env-mediated cell-cell fusion
Compounda
IC50 (nM)b
CCR5-tropic fusion assay CXCR4-tropicfusion assay
CCR5-tropic fusion assay
with competition
CCR5-tropic fusion assay with
washout on HeLa-ADA cells
Griffithsin 1.31 0.87 0.468  0.27 1.73  0.60 4.28  1.50
Griff37 0.148 0.05 (2.98 105) 0.088  0.03 (0.046) 0.369 0.03 (0.000067) 3.39 0.56 (0.0588)
Griffithsin  C37 (1:1) 0.911  0.37 0.542  0.39 1.04  0.23 6.23  1.7
Griff37(Q652L) 0.121 0.06 (7.70 106) 0.167  0.09 (0.063) ND ND
Griffithsin  C37(Q652L) (1:1) 2.01 0.66 1.35  0.65 ND ND
C37CD4M33C1F23
c 6.84  2.9 2.30  0.98 7.78  1.6 77.8  1.2
GriffCD4M33C1F23
c 3.47  0.97 1.19  0.44 12.6  1.4d ND
C37 18.2  7.5 2.70  1.3 61.4  7.9 No inhibition
C37(Q652L) 28.2 8.3 ND ND ND
CD4M33 	1,000 	1,000 ND ND
a A 1:1 ratio indicates equal molar amounts.
b IC50s for all combinations are reported as total protein concentrations. Each experiment was carried out in triplicate and was repeated at least 3 times except where
otherwise noted. The IC50s were calculated as the averages of the values obtained for the independent experiments  standard deviations. Numbers in parentheses
are the P values resulting from a t test comparing the indicated compound with griffithsin plus C37. A P value of 
0.05 is considered statistically significant. ND, not
determined. The peptide C37 is a product of chemical synthesis and is capped at both ends, with N-terminal acetylation and C-terminal amidation.
c CD4M33C1F23 is a recombinantly produced protein based on the synthetically produced peptide CD4M33 designed by Martin et al. (38).
d This experiment was carried out in triplicate and was repeated twice.
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acids in positions 1 and 23, we replaced these with the natural
amino acids Cys and Phe, respectively, in order to allow ex-
pression in E. coli. We refer to this peptide as CD4M33C1F23.
In CCR5-tropic fusion assays, C37-linker-CD4M33C1F23
(C37CD4M33C1F23) exhibited an IC50 of 6.84 2.9 nM (Table
1). This value is significantly lower than that for either com-
ponent alone in cell-cell fusion assays, since C37 has an IC50 of
18.2 nM, and His tag-containing CD4M33C1F23 was not an
effective inhibitor even at our highest tested concentration of
1.4 M (data not shown). Synthetically produced CD4M33
(38) had an IC50 higher than 1,000 nM in our hands in this
fusion assay (Table 1). We also produced the compound
griffithsin-linker-CD4M33C1F23 (GriffCD4M33C1F23), which
could provide two molecules that bind to gp120. This com-
pound performed reasonably well in CCR5-tropic cell-cell fu-
sion assays, with an IC50 of 3.47  0.97 nM, but did not appear
to have enhanced activity compared to the individual compo-
nents of the molecule.
These results suggest the possibility that combining a gp120-
binding protein (such as griffithsin or CD4M33) with a gp41-
binding protein (such as C37) is a potent strategy for the
inhibition of CCR5-tropic HIV.
Strategically linked compounds are potent in CXCR4-tropic
cell-cell fusion assays. The linked combination of griffithsin
and C37 was also quite potent in CXCR4-tropic cell-cell fusion
assays. As shown in Fig. 1 and Table 1, while griffithsin alone
exhibited an IC50 of 0.47  0.27 nM, the linked Griff37 was
5.3-fold more potent, with an IC50 similar to that of the point
mutant of the linked compound, Griff37(Q652L) (Table 1).
When unlinked, the combination of griffithsin and C37 was
only slightly more potent than either compound alone (Fig. 1B
and Table 1).
When C37 was linked with the gp120-binding peptide
CD4M33C1F23, the resulting compound, C37CD4M33C1F23,
had an IC50 of 2.30  0.98 nM. Since this is close to the value
for C37 alone, and CD4M33 has been shown to inhibit in a
CXCR4-tropic fusion assay in the micromolar range (IC50,
0.8  0.09 M) (38), it appears that linking the two inhibitors
in this case does not improve inhibition. Interestingly, these
results differ from those for the CCR5-tropic cell-cell fusion
assay, where the C37CD4M33C1F23 compound had an IC50
lower than that of either compound alone (Table 1).
Strategically linked compounds perform well in viral and
pseudoviral assays. To confirm that the strategy of linking a
gp120-binding protein with a gp41-binding peptide is suc-
cessful in inhibiting HIV replication, a series of assays were
performed using several types of target cells and viral
strains. In replication-competent HIV assays, the linked
compound Griff37 consistently performs better than griffithsin
alone. For example, when the CCR5-tropic HIV-1 strain Ba-L
is used to infect MAGI cells, griffithsin alone exhibits an IC50
of 0.04  0.01 nM, while Griff37 is 2.7-fold more potent, with
an IC50 of 0.015 0.005 nM (Table 2; Fig. 2), and the unlinked
combination of griffithsin and C37 has an IC50 of 0.05 nM for
each protein. Similarly, when the CCR5-tropic HIV-1 strain
ADA infects MAGI cells, Griff37 is 2-fold more potent than
griffithsin alone and 6.3-fold more potent than the unlinked
combination of griffithsin and C37 (total-protein concentra-
tion) (Table 2). The effect in most cases is even more dramatic
when the IC90s of these compounds against viral strains are
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compared. For Ba-L, Griff37 is 6.4-fold more potent than grif-
fithsin and 9.4-fold more effective than the unlinked combi-
nation (Table 2), and similar results are observed for the
inhibition of strain ADA.
As described for fusion assays, these compounds are also
highly effective against CXCR4-tropic HIV strains. When
MAGI cells are infected by the CXCR4-tropic strain HIV-1
IIIB, Griff37 again shows severalfold higher potency than its
components (Table 2).
Similar results are observed when human PBMCs are in-
fected with HIV-1 Ba-L. In this case, griffithsin alone has an
IC50 of 0.28  0.17 nM, while Griff37 is 4.7-fold more potent,
with an IC50 of 0.059  0.0004 nM, and the unlinked compo-
nents griffithsin plus C37 are less than 2-fold more potent than
griffithsin alone (Table 3). When the CCR5-tropic HIV-1 clin-
ical isolate 91US005 is used to infect PBMCs, the result is
about a 4-fold improvement for Griff37 over griffithsin alone
(Table 3). Griff37 also shows a 3.8-fold increase in anti-HIV
potency over griffithsin alone for the CXCR4-tropic strains NL4-3
and 92HT599 (primary strain; Table 3). Since the griffithsin-
containing compounds were clearly more potent than the
CD4M33C1F23-containing compounds, the CD4M33C1F23 com-
pounds were not tested in replication-competent viral as-
says.
In single-round infection assays, griffithsin and its analogs all
perform quite well. HIV virions pseudotyped with Env from
the CCR5-tropic HIV-1 strain JR-FL or ADA were used in
inhibition assays. While Griff37 performed marginally better
(as determined by the IC50) than griffithsin alone with strain
JR-FL, it did not perform better with strain ADA (Table 4).
Indeed, the use of strain ADA in a single-round infection assay
was the only instance we identified in which Griff37 was not
superior to griffithsin (Tables 1, 2, 3, and 4). Mutation to disrupt
the activity of the C37 component of Griff37 [Griff37(I642D)]
showed a loss of activity against the JR-FL strain, while mu-
FIG. 2. HIV assays. Both griffithsin and the linked compound
Griff37 were tested for inhibition of ADA and Ba-L virus strains in
infection assays against MAGI cells. Griff37 (inverted triangle, against
strain ADA; square, against strain Ba-L) performs better than griffith-
sin (diamond, against strain ADA; circle, against strain Ba-L) in both
cases. For Griff37, the two lines are nearly overlapping.
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tation to shorten the linker (Griff37-shortlink) resulted in a
protein that was still quite potent, with an activity close to that
of Griff37 (Table 4). In addition, the combination of the gp41-
binding peptide C37 with gp120-binding CD4M33C1F23, desig-
nated C37CD4M33C1F23, also appears to perform moderately
better in CCR5-tropic pseudoviral assays than the component
C37 alone (13-fold), recombinant CD4M33C1F23 (not ac-
tive), or synthetic CD4M33, which Martin et al. showed to
exert nanomolar inhibition in other strains, although in our
hands inhibition by CD4M33 alone was less effective (Table 4)
(38). Again, this indicates that the combination of a gp120-
binding molecule with a gp41-binding molecule can be a potent
HIV inhibition strategy, particularly since the CD4M33 com-
ponent of our C37CD4M33C1F23 was not optimized for amino
acid usage or foldedness during preparation.
Strategically linked compounds maintain effectiveness in
competition assays and in washing assays. For a potential
therapeutic to be beneficial in an organism, it needs to be able
to find its target effectively in the milieu of other cell types and
potential binding partners. As a test of this ability, the CCR5-
tropic cell-cell fusion assay was modified by the addition of
mouse 3T3 fibroblasts, which serve as a connective tissue sur-
rogate, supplying proteins and carbohydrates. These cells can-
not be infected by HIV and do not have human coreceptors on
their surfaces, but they present a myriad of proteins and car-
bohydrates that could potentially bind an anti-HIV therapeutic
and confound its ability to inhibit in the assay.
As we previously reported, in a CCR5-tropic fusion assay,
the peptide C37 performs significantly worse in the presence of
unrelated competitor cells than in the absence of such cells,
with an IC50 of 61.4  7.9 nM (27) (Table 1). This leads to the
possibility that Griff37 also performs worse in the presence of
unrelated cells due to the presence of C37. However, the
linked compounds perform quite well under these conditions.
The presence of competitor cells does not greatly affect grif-
fithsin-containing compounds, since griffithsin alone still per-
forms well. But Griff37 again performs significantly better than
griffithsin alone (Table 1). When C37 is linked to the gp120-
binding peptide CD4M33 to make C37CD4M33C1F23, the re-
sulting IC50 is 7.78  1.6 nM, which is close to the value in the
absence of competition. Similar results were also observed for
Griff37 in single-round infection assays using virus pseudotyped
with Env from the CCR5-tropic HIV-1 strain JR-FL in the
presence of competitor cells. In these experiments, all griffith-
sin-containing compounds performed well, but Griff37 per-
formed better than griffithsin alone (data not shown).
To determine whether the linked inhibitors maintain some
of their activity under washout conditions, modified R5 fusion
assays were carried out. In these assays, either the target cells
or the effector cells were placed in a well in the presence of an
inhibitor. The supernatant was then removed; cells were
washed twice with PBS; and inhibitor-free medium was added,
followed by the addition of the other cell type to allow fusion
to proceed. Therefore, inhibition would be observed only for
inhibitors that can maintain their presence rather than be
washed away. In these assays, the IC50 of C37 could not be
determined, because it was apparently fully washed out. How-
ever, both griffithsin and Griff37 maintained nanomolar effec-
tiveness when they first bound to the ADA “HIV effector cells”
before the washing step. It is worth mentioning that when the
inhibitors were incubated with the target cell before the wash-
ing step, vigorous washing was needed to wash away griffithsin
and Griff37, indicating a low level of nonspecific binding of
griffithsin to the cell surface (data not shown). This low level
of nonspecific binding does not affect the anti-HIV potency of
griffithsin, as indicated both by a competition assay (Table 1)
and by a control experiment utilizing single-round HIV virions
pseudotyped with SVA-murine leukemia virus (MuLV), which
would not be expected to be inhibited by griffithsin. (Griffithsin
inhibits SVA-MuLV with an IC50 of 	6.8 M [	100 g/ml]
[41].) Overall, these experiments indicate that under physio-
logical conditions where many different cell types and fluids
may be present, these inhibitors maintain very high effective-
ness, in contrast to C37 alone.
NMR experiments on anti-HIV compounds. Nuclear mag-
netic resonance (NMR) is a very effective technique for deter-
mining the structural details of proteins, including the extent of
their foldedness and the possibilities for their oligomeric state
(9, 17, 34). Figure 3A shows the 15N-1H correlation spectrum
(15N heteronuclear single quantum coherence [HSQC] spec-
TABLE 4. Inhibition of HIV single-round pseudovirus in TZM-bl cells
Compound
Inhibitiona of:
ADA (CCR5 tropic) JR-FL (CCR5 tropic)
IC50 (nM) IC90 (nM) IC50 (nM) IC90 (nM)
Griffithsin 0.022 0.01 0.428 0.23 0.035 0.01 1.25 0.19
Griff37 0.042 0.02 (0.25) 0.240 0.04 (0.81) 0.025 0.02 (0.63) 0.260 0.10 (0.0003)
Griffithsin  C37 (1:1) 0.021 0.02 0.277 0.18 0.032 0.02 1.38 0.39
Griff37(Q652L) 0.023 0.01 (0.70) 0.274 0.07 (0.52) ND ND
Griff37-shortlink 0.078 0.07 (0.13) 0.352 0.28 (0.70) 0.046 0.01 (0.25) 0.315 0.01 (0.06)
Griff37(I642D) 0.061 0.02 (0.04) 0.298 0.03 (0.89) 0.082 0.01 (0.005) 0.919 0.02 (0.49)
Griffithsin  C37(Q652L) (1:1) 0.021 0.01 0.374 0.19 ND ND
C37CD4M33C1F23 2.33  2.8 17.3 17 2.25 1.4 24.3 20
GriffCD4M33C1F23 0.222  0.02 2.69 0.23 0.270 0.15 2.89 0.25
C37 27.2  17 637 290 15.2 4.2 462 360
C37(Q652L) 114 5 ND ND ND
a IC50 and IC90 values (nanomolar concentrations) were determined for single-round pseudovirus assays. Numbers in parentheses are P values resulting from a t test
comparing the indicated compound with griffithsin plus C37. A P value of 
0.05 is considered statistically significant. Each experiment was carried out in triplicate and
repeated at least three times. The IC50 and IC90 values were calculated as the averages of values for independent experiments  standard deviations. ND, not
determined.
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trum) of griffithsin alone, which is a 121-amino-acid protein
that crystallizes as a dimer (62). This type of spectrum shows
one peak for every N-H pair in the protein and therefore
provides a fingerprint that is unique for each protein. The spec-
trum of griffithsin shows good peak dispersion in the 1H dimen-
sion with well-resolved peaks, strongly suggesting a nicely folded
protein, as would be expected for a stable, wild-type, relatively
low molecular weight protein.
Figure 3B shows the spectrum of the linked compound
Griff37. Although this protein exhibits potent anti-HIV activity
in numerous assays, the spectrum shows a strong signal around
8.2 ppm in the 1H dimension, indicative of unfolded or random
coil protein in the sample. There are also peaks (of lower
intensity) in the “folded” region of the spectrum (particularly
above 9 ppm), and an overlay of this spectrum with griffithsin
alone indicates that these peaks arise from folded griffithsin
(overlay not shown).
NMR experiments were also carried out on the
C37CD4M33C1F23 peptide combination. Since this compound
is a fusion of two peptides (albeit functionally active peptides),
the unfolded peaks that are observed in the 8.2-ppm region of
Fig. 3C were expected. However, there were also peaks indic-
ative of folded protein (several of which are circled in Fig. 3C).
Since C34 (nearly identical to C37) has been shown to be
unfolded in the absence of its gp41-binding partner (36), it is
likely that the peaks in this region of the spectrum result from
folded CD4M33C1F23. The parent compound, CD4M33, was
designed by Martin et al. to be a folded peptide containing
unnatural amino acids and was produced for their work by
chemical synthesis (38). Therefore, it is notable that although
we made multiple changes to CD4M33, including the use of
“natural” amino acids to replace the designed unnatural amino
acids, the use of recombinant expression rather than synthesis,
and linkage with another peptide, the resulting protein still is
an active anti-HIV compound that is at least partly folded.
DISCUSSION
Many binding targets, both on the HIV-1 virion and on the
human cell, have been established as effective sites for HIV
inhibition. But an underexplored area for HIV inhibition is to
elucidate an overall strategy, possibly combining multiple in-
hibitors, that optimizes the effectiveness of inhibition under a
number of different conditions and with different viral strains.
The present work examines the possible benefits of combining
a gp120-binding and a gp41-binding moiety in a single com-
pound. It was found that such a strategy consistently performs
well both in cell-cell fusion assays and in viral assays, using
both CCR5- and CXCR4-tropic strains, as well as under con-
ditions of competition and washing out. In most cases, the
linked compounds performed better than their parent com-
pounds, most strikingly in the improvement of the already
highly potent protein griffithsin.
Griffithsin has shown a great deal of promise in tests of its
anti-HIV microbicidal characteristics. In addition to its re-
markably high potency, it is stable upon incubation at 37°C, a
necessary property if it must remain active in the human body
for hours or be stored without refrigeration (16). It also retains
its activity in cervical/vaginal lavage fluid (16), is noninflam-
matory in human cervical explants, is nonirritating in a rabbit
vaginal model, and is active against multiple clades of HIV,
indicating likely usefulness in many or all of the areas hardest
hit by this disease (41).
The most effective inhibitor in our experiments was Griff37,
or possibly its slight variant Griff37(Q652L), both compounds
that covalently link griffithsin with the C-peptide C37. This
FIG. 3. 15N-1H correlation spectra of some of the HIV inhibitors
used in this study. (A) Wild-type griffithsin; (B) Griff37 (griffithsin
linked to C37); (C) C37CD4M33C1F23. Circled peaks on this spectrum
indicate resonances that are consistent with folded protein.
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linked inhibitor performed at subnanomolar levels in both
CCR5- and CXCR4-tropic fusion assays and at midpicomolar
levels in viral assays. These values are in almost every case
better than those for griffithsin alone and better than those for
an unlinked combination of griffithsin and C37 (Tables 1, 2, 3,
and 4). This indicates that the linked combination of inhibitors
is indeed more potent than the individual components and is
worthy of strong consideration as a microbicide or therapeutic.
These effects are not likely due to synergistic action of the two
inhibitors, because an examination of the combination index
(an indicator of synergy [7]) showed essentially no synergy of a
1:1 combination in fusion or viral assays and, in fusion assays,
no synergy for 1:10, 1:30, or 1:300 ratios of griffithsin to C37
(data not shown).
In the replication-competent viral assays, the improvement
in the IC90 for the linked compound Griff37 was more statis-
tically significant than the improvement in the IC50; this is a
positive indicator, since 90% inhibition is perhaps more critical
for truly stopping infection. Statistical significance is judged by
a comparison of the P values derived from the Student t test as
described in Materials and Methods. The tables in the supple-
mental material also contain P values for a comparison of the
linked compounds with their unlinked controls for many of the
types of assay presented here. The greater effectiveness of
Griff37 at the higher concentrations needed for 90% inhibition
in the viral assay could be explained partly by the increasing
importance of the C37 component at these concentrations,
because C37 inhibits at nanomolar levels. As the concentration
of the inhibitor rises from picomolar levels (where griffithsin
functions, based on its IC50), to nanomolar levels, the C-pep-
tide may contribute more to the overall inhibition. As a further
test of the strategy of covalently linking a gp120-binding com-
pound with a gp41-binding compound, the linked peptide
C37CD4M33C1F23 was produced. Again, this compound con-
sistently showed more-potent inhibition than either compo-
nent alone in the CCR5-tropic cell-cell fusion assay (Tables 1
and 4).
In deriving a set of possible models to explain the effective-
ness of Griff37, each model must account for the fact that this
linked molecule is a significantly better inhibitor than the un-
linked combination of the two components. In keeping with
this observation, there are at least three plausible models for
the mechanism of action of Griff37. The first model is that the
griffithsin moiety binds to gp120 with high affinity, and the role
of the linked C37 is simply to provide a more sizeable protein
on gp120 (Fig. 4A), making a more effective blockade against
binding to CD4 or CCR5. However, arguing against this simple
steric mechanism is the evidence that griffithsin linked to the
peptide CD4M33 (GriffCD4M33C1F23) would also be expected
to be able to provide a similar binding blockade, yet this mol-
ecule does not show enhanced inhibition compared to griffith-
sin alone. Also, Griff37(I642D), which carries a substitution
that negatively affects the binding of C37 to gp41, shows de-
creased activity. This indicates that C37 function is important
to the activity of the linked compound. A second model is one
in which the griffithsin component binds to gp120, thereby
delivering C37 close to its binding site on gp41. By being in
physical proximity to gp41, C37 is able to bind gp41 and to
inhibit fusion if and when gp41 is exposed, possibly dislodging
the linked griffithsin at that time. In this scenario, it is assumed
that only one component of the linked pair is binding to its site
at any given time, although they may both be in an on-off
equilibrium with their respective binding sites (Fig. 4B). Note
that griffithsin is a tight dimer (62, 63), so Griff37 likely brings
two molecules of C37 to a single viral spike, although for the
sake of simplicity, the dimer structure is not shown in Fig. 4.
In the third model of action for Griff37, both components
(i.e., griffithsin and C37) are bound to their respective targets
simultaneously. The 16-amino-acid linker used in Griff37 was
designed to be flexible and to allow simultaneous binding of
the two components even if the binding sites are fairly distant.
For example, an 8-amino-acid extended chain in griffithsin
spans about 24 Å, so a 16-amino-acid linker could potentially
allow binding at sites tens of angstroms apart. In the structure
and the structural model provided by Chen et al. in their work
on unliganded simian immunodeficiency virus (SIV) gp120 (6),
much of the surface of gp120 is close enough to gp41 to allow
simultaneous binding of griffithsin and C37.
In order to address whether the model presented in Fig. 4B
or that presented in Fig. 4C is more correct, a shortened linker
was constructed for Griff37, and the compound was called
Griff37-shortlink. We reasoned that if both griffithsin and C37
FIG. 4. Possible models of action of the linked compound Griff37. Note that griffithsin may act as a dimer, which is not depicted in this
simplified figure. (A) The inhibitory action of the molecule is due to the binding of griffithsin to gp120, but extra steric blocking is provided by C37.
(B) Inhibition is provided by either griffithsin or C37, but only one is properly bound to its target at any given time. (C) Inhibition is provided by
griffithsin and C37, both of which are bound simultaneously to their respective targets (gp120 and gp41).
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bound simultaneously to their targets (as in Fig. 4C), a short-
ened linker would significantly reduce activity (down to the
level of griffithsin), since this length is likely not sufficient for
simultaneous binding. We found that in cell fusion assays,
Grif37-shortlink did inhibit less well than Griff37, indicating
that linker length is important in this type of assay. In contrast,
Griff37-shortlink inhibited similarly to Griff37 in single-round
viral assays (Table 4). Since a single-round infection assay is
more representative of a replication-competent viral infection,
we believe that the model in Fig. 4B, showing nonsimultaneous
binding of griffithsin and C37, is more likely. Experiments are
ongoing in this regard.
Like the results for Griff37, the experiments reported here
with other linked peptides also indicate the beneficial effects of
binding both gp120 and gp41, although the production in E.
coli without optimization leaves open the possibility that the
effect could be stronger after refolding conditions are im-
proved. The compound C37CD4M33C1F23 inhibits in CCR5-
tropic fusion assays better than either component alone and is
particularly effective in washing assays, indicating the advan-
tage of a bifunctional compound. Small differences in IC50s
between C37 and the linked compound C37CD4M33C1F23 in
the CXCR4-tropic cell-cell fusion assay may be explained by a
lower affinity of CD4M33C1F23 for HXB2 Env. It should be
noted that the values for our version of CD4M33C1F23 are
expected to be significantly less favorable than the values re-
ported for the CD4M33 peptide, since our version is fully
recombinant without the benefit of selectively designed unnat-
ural components. Another important point is that the high
number of cysteines (6 total) in C37CD4M33C1F23 could allow
for potentially different combinations of S-S bonds, leading to
unfolded protein. Even if C37CD4M33C1F23 shows several
folded peaks in the NMR spectrum, it is not clear that any or
all of the proper disulfide bonds are formed. Therefore, it is
possible that CD4M33C1F23 does not have the proper folding
to bind as tightly to gp120 as the chemically synthesized pep-
tide CD4M33. Even with these drawbacks, it is fairly easy and
economical to produce C37CD4M33C1F23, and its relatively
small size makes it an attractive candidate for further improve-
ment.
It is possible that the linked compounds offer additional
advantages aside from improved potency and their potential as
microbicides. The C-peptide T-20 is clinically approved but
requires frequent dosing due to a short lifetime of only hours
in vivo (54). It has been shown that linking the similar peptide
C34 with albumin (a larger protein) allows for high detectable
concentrations of the linked compound in the plasma of rats
for days, suggesting that linking a C-peptide with a larger
protein may delay renal clearance and/or susceptibility to pro-
tease degradation (54). Our experiments involve the protein
C37, which, like T-20, is derived from the sequence of gp41 and
which is identical to C34 except for an additional 3 amino acids
on the N terminus. It is possible that Griff37 has an in vivo
lifetime of several days due to its larger size, like albumin-
linked C34 (54). In addition, an advantage of a drug with two
different sites of action is the difficulty of viral escape, since
viral mutations to escape from one of the linked inhibitors
would be expected to have little or no effect on the other
inhibitor.
Other groups have also investigated the strategy of linking
HIV inhibitors in order to increase effectiveness. One very
effective linked compound is an anti-CD4 antibody having each
heavy chain extended with a gp41-binding C-peptide. This chi-
meric protein showed HIV inhibition with an IC50 as low as 14
pM in single-round HIV assays (25, 26). This group also pro-
duced another excellent compound by linking an anti-CCR5
antibody with a C-peptide (30). In both cases, the antibody was
expressed with one C-peptide at the C terminus of each heavy
chain of the antibody, resulting in a C-peptide/antibody ratio of
2:1. While both of these chimeric compounds would likely be
highly effective microbicides, they have the disadvantage of
being produced in a mammalian cell system (HEK cells), which
would make it difficult to produce gram quantities of the in-
hibitor. In our system, Griff37 was produced from E. coli in
shaker flasks and could likely be produced in large quantities
by fermentation or in a plant-based expression system, both
processes that were recently shown to be useful in making large
quantities of functional griffithsin (22, 41). Another effective
HIV inhibitor was produced by linking two domains from CD4
with a single-chain variable region from antibody 17b, which is
known to interact with gp120 on a site near its CCR5-binding
region. This inhibitor was shown to be effective at nanomolar
levels and was expressed by recombinant vaccinia virus (14). A
recent study of an anti-gp120 antibody in various monomeric/
dimeric covalent configurations and an anti-gp41 antibody in
these configurations also showed the importance of multiva-
lency in HIV inhibition (29).
Structurally, the 1H, 15N correlation spectrum of griffithsin
alone shows a nicely dispersed set of peaks indicative of a fully
folded protein (Fig. 3A). To our knowledge, this is the first
NMR spectrum reported for griffithsin, although several high-
quality X-ray structures have been determined (62–64). The
benefit of NMR spectra is that comparisons between variants
of a protein can be made quickly and easily without the need
for a full structural determination if sequence assignments
have been completed. Such work for griffithsin is ongoing.
The NMR spectra of the strategically linked compounds
show some resonances to indicate that both Griff37 and
C37CD4M33C1F23 are folded, although it is not clear what
percentage of each sample is folded. For Griff37, there are
several likely explanations for the presence of strong peaks in
the unfolded region of the spectrum even though the protein is
quite active. First, the 16-amino-acid linker between griffithsin
and C37 was designed to be structurally flexible, so the signal
from this region is expected to resonate in the “unfolded”
region of the spectrum. Second, the C37 peptide is likely un-
folded in the absence of a binding partner (35), which would
lead to peaks in the unfolded region of the spectrum due to this
peptide, even if the peptide would be fully active when pre-
sented with a binding partner in an assay. Finally, if the Griff37
protein forms oligomers or loose aggregates, line broadening
would occur, which would have the effect of decreasing the
intensities of all the peaks, particularly those from residues
that are not free to move quickly in solution. Therefore, a
globular protein such as griffithsin would be expected to lose a
great deal of signal intensity upon oligomerization. Overall, the
spectrum of Griff37 suggests a sample that is at least partially
folded (due to the clear presence of peaks that overlap with
those in the griffithsin sample) but that may have a portion
unfolded and/or in an oligomerized state. In this case, small
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improvements to the refolding procedure may lead to signifi-
cantly more-potent inhibitors.
The strategically linked compounds reported here show pi-
comolar levels of activity in many assays, but further improve-
ments may be possible. For example, it may be possible to
improve the C-peptide component by capping the charged
ends that occur naturally when a protein is expressed rather
than synthesized (53). In our hands, N-acetylated, C-amidated
C37 inhibits in the CCR5-tropic fusion assay with an IC50 of
18.2 nM, as reported above. However, C37 without the termi-
nal modifications inhibits with an IC50 of	100 nM. Therefore,
it is possible that capping the C-terminal ends of Griff37 and
C37CD4M33C1F23 could increase the potencies of these com-
pounds. In addition, others have reported further improve-
ments in C-peptides that increase their potencies (12); it may
be possible to incorporate such improvements into the strategy
presented here.
This paper presents evidence that the strategy of linking a
gp120-binding molecule with a gp41-binding molecule can lead
to a compound that has greater anti-HIV activity than its
individual components alone or in combination. It was dem-
onstrated that the highly potent microbicidal candidate grif-
fithsin could be made even more potent by using this strategy.
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